Clinical Trial

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies…

1 week ago

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

From giving AI the sense of smell and breakthrough in rare disease treatments, Ainos is shaping 2025 with bold technologies…

1 week ago

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to…

1 week ago

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec.…

1 week ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the…

1 week ago

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Trial will evaluate the safety, pharmacokinetics and pharmacodynamics of RPT1G in adult healthy volunteers in anticipation of their upcoming oncology…

1 week ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -…

1 week ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq:…

1 week ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the…

1 week ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with…

1 week ago